ClinicalTrials.gg
RecruitingNCT07454616RtMUpdated Mar 6, 2026

Exploratory Study on a Multi-nutrient Supplement and Exercise Program for Improving Health Markers Associated to Longevity in Pre-frail Adults

An interventional study of Supervised exercise program and a balanced micronutrient blend in Pre-Frailty and Aging, sponsored by National University of Singapore. Recruiting at 1 site in Singapore. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by National University of Singapore · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Sep 2025, registered Feb 2026).
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Frailty with a site in Singapore — 12 open to participants now, 13 under way, none of them phase 3. Frailty · Singapore.

Planned enrollment
20th of 21
40 · median 140
Started
2025
with 4 others
No phase
20 of 28
9 open now
Primary completion
2026-04
later than 4 of 12 live
Registered
25th of 28
by date
Lead sponsor
6 of 28
National University of Singapore

Among the 28 studies in Frailty with a site in Singapore, this one is the 20th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 20 with no phase, reaches primary completion later than 4 of the 12 other live ones, and was the 25th registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

12 of the 28 studies in Frailty with a site in Singapore are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Frailty with a site in Singapore, or all of them as a file.
02

Study summary

Frailty is associated with biological changes in the gut microbiome and immune system, along with marked declines in physical and cognitive function, leading to an overall reduction in quality of life. Prefrailty represents an early stage where interventions may prevent or reverse these declines. This study aims to evaluate whether a 12-week combined Synbiotic enriched oral nutritional supplement and supervised exercise program can improve muscle strength and mass, gut microbiome composition, immune function, and cognitive performance in prefrail adults aged 50-80 years.

Read the detailed description

As we age, biological age, gut microbiome, muscle, immune, and cognition undergo gradual decline. Aging is associated with progressive declines in multiple physiological systems which affects healthspan (years free from diseases). Skeletal muscle undergoes atrophy and functional impairment, characterized by reductions in muscle fiber size and number. Cognitive decline occurs with age and is associated with structural and functional brain changes, contributing to impairments in memory, attention, and executive function. The aging immune system exhibits immuno-senescence, marked by diminished adaptive immune responses, altered T-cell function, and chronic low-grade inflammation. To reduce the healthspan-lifespan gap, Healthy Longevity Medicine (HLM) aims to optimise health and healthspan by targeting the ageing processes across the lifespan. To help mitigate these age-related changes, research is increasingly focused on developing targeted interventions such as nutritional supplements and structured exercise programs. Objective: To explore the effects of a 12-week intervention including supervised exercise and a Synbiotic enriched oral nutritional supplement on gut (microbiome), muscle, immune, cognition and biological age outcomes in pre-frail individuals aged 50-80 years. Study design: This is a single-arm, open-label, interventional, exploratory, single-centre study in which 40 pre-frail male and female individuals aged 50-80 years will be administered a novel multi-nutrient supplement containing synbiotics combined with supervised exercise for a total of 12 weeks.

03

Conditions studied

  • Pre-Frailty
  • Aging

Browse trials for

Keywords

  • Prefrail elderly
  • Gut microbiome
  • Nutritional supplementation
  • supervised exercise
  • Biological age markers
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Singapore residents of all ethnic groups
  2. Adults aged 50-80 years (both male and female)
  3. (BMI) ≥18 kg/m²
  4. Classified as Prefrailty according to Fried frailty criteria
  5. Willing and able to attend all data collection visits and to comply with the exercise and supplementation protocols.
  6. Able and willing to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Current use of supplements containing: Bifidobacterium longum 536 (BB536) like Kordel's BB536 bifidus; Bifidobacterium longum such as GniiB immunity; GOS (Galacto-oligosaccharides); FOS (Fructo-oligosaccharides); Inulin or any commercial healthy-aging powdered milk products
  2. >30 kg/m2 3 Being on special diets including but not limited to ketogenic diets or diets prescribed by a healthcare professional

4. Received any vaccination within the past 8 weeks. 5. Inition of new medication or use of medications affecting gastrointestinal function within the past 8 weeks, including but not limited to antibiotics or Proton pump inhibitors 6. Known allergies or intolerances, including, soy allergy; fibre allergy (e.g., GOS) or requirement for a fibre-free diet; fish allergy; Cow's milk protein allergy or lactose intolerance; galactosaemia 7. More than two unstable chronic conditions (e.g., hypertension, diabetes, hyperlipidemia, osteoarthritis, ) 8. Medical conditions for which probiotic use is , including but not limited to individuals, astrointestinal failure or severe gastrointestinal disturbances (e.g., blood in stool), presence of a central venous catheter, open wounds following surgery 9. Contraindications to oral feeding, including gastrointestinal failure, complete intestinal obstruction, inability to access the gut or high loss intestinal fistulae 10. Known renal disease were unable to tolerate 2 servings per day. 11. Intake of supplemental calcium >500 mg/day or vitamin D >40 µg/day (1600 IU) from all sources, including diet and supplements 12. Use of medications that may interact with or impair absorption of milk products (e.g., tetracyclines) 13. Any other condition deemed by PI that may compromise participant safety and study compliance.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    The participants will be administered a powder oral nutritional supplement containing a synbiotic blend of prebiotics and probiotic, a protein blend and a micronutrient blend, combined with supervised exercise for a total of 12 weeks.

    Behavioral: Supervised exercise program · Dietary Supplement: a balanced micronutrient blend

Interventions

  • BehavioralSupervised exercise program

    A supervised exercise intervention consisting of resistance and endurance training, delivered two times per week, with each session lasting 60 minutes, conducted by an exercise physiologist in the gym's clinic in Singapore.

  • Dietary supplementa balanced micronutrient blend

    A balanced micronutrient blend containing soral nutritional supplement in powder form containing a synbiotic blend of prebiotics and probiotic, a protein blend and a micronutrient blend provided by Danone Global R\&I Center. The participant will be required to take two servings of the study product daily for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change in muscle mass measured via B- mode ultrasound

    Change from baseline to Week 12 in muscle mass assessed by muscle thickness measured using B-mode ultrasound. Muscle thickness was measured in centimeters (cm) at a predefined anatomical site

    Time frame: Baseline and 12 weeks

  2. Change on Fecal Bifidobacterium level measured via stool microbiome analysis

    Change from baseline at 6 and 12 weeks in stool Bifidobacterium abundance, measured by quantitative PCR (qPCR), and in microbiome diversity, measured by 16S rRNA gene sequencing and shotgun metagenomic sequencing.

    Time frame: Baseline, 6 weeks and 12 weeks

Secondary outcomes

  1. Change in cognitive performance National Institutes of Health Toolbox Cognition Battery - Fluid composite

    Change from baseline to 12 weeks in cognitive performance assessed by the National Institutes of Health Toolbox Cognition Battery - Fluid composite. \[scores of 0 to 100 in raw or age-corrected scaled score\]

    Time frame: Baseline and 12 weeks

  2. Change in the immune function (CD4+: CD8+ ratio)

    Change from baseline at 6 weeks and 12 weeks in CD4+: CD8+ in T-cell ratio

    Time frame: Baseline, 6 weeks and 12 weeks

  3. Change in cardiorespiratory fitness (Peak VO₂)

    Change from baseline to 12 weeks in maximal oxygen uptake (VO₂peak) assessed using standardized cardiopulmonary exercise testing (mL/kg/min)

    Time frame: Baseline and 12 weeks

  4. Change in Muscle Strength assessed using 1RM strength test

    Change from baseline to 12 weeks in 1RM strength (Smith machine bench press) (Kg)

    Time frame: Baseline and 12 weeks

  5. Change in Handgrip Strength Measured by Dynamometer

    Change from baseline to Week 6 and Week 12 in handgrip strength measured using a calibrated handgrip dynamometer. Grip strength was recorded in kilograms (kg) according to standardized testing procedures.

    Time frame: Baseline, 6 weeks and 12 weeks

  6. Stool consistency, frequency and gastrointestinal tolerance

    Stool consistency and frequency will be measured during the study. Gastrointestinal tolerance will be evaluated through participant-reported symptoms.

    Time frame: baseline, 12 weeks

  7. Change in Biological age determined by DNAm clocks

    Change from baseline to 12 weeks in biological age derived from DNA methylation profiling

    Time frame: baseline, 12 weeks

  8. Change in advanced glycation end-products (AGEs) assessed using skin autofluorescence.

    Change from baseline to 12 weeks in circulating and/or tissue levels of advanced glycation end-products (AGEs), assessed using skin autofluorescence (AU).

    Time frame: Baseline, 12 weeks

  9. Change in inflammatory markers (IL-6, IL-10, TNF-α and IFN-γ)

    Change from baseline to Week 6 and Week 12 in serum inflammatory markers including interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ). Concentrations were measured in picograms per milliliter (pg/mL) using validated laboratory assay methods.

    Time frame: Baseline, 6 weeks and 12 weeks

  10. Change in immune function as measured by Lymphocyte/neutrophil ratio

    Change from baseline to 6 weeks and 12 weeks in Lymphocyte/neutrophil cells ratio

    Time frame: Baseline, 6 weeks and 12 weeks

  11. Change in blood pressure measured using SphygmoCor-XCEL

    Change from baseline to Week 6 and Week 12 in systolic blood pressure (SBP) and diastolic blood pressure (DBP) measured in millimeters of mercury (mmHg) using the AtCor Medical SphygmoCor XCEL device.

    Time frame: baseline, 6 weeks, 12 weeks

  12. Change in Arterial stiffness measured via SphygmoCor-XCEL

    Change from baseline to Week 12 in arterial stiffness assessed using the AtCor Medical SphygmoCor XCEL device. Arterial stiffness was evaluated by carotid-femoral pulse wave velocity (cfPWV), reported in meters per second (m/s).

    Time frame: Baseline and 12 weeks

  13. Change in Physical Activity Levels Measured by Wearable Devices

    Change from baseline to Week 12 in physical activity levels (daily steps) assessed using wearable devices (e.g., OURA ring).

    Time frame: baseline, 12 weeks

  14. Change in heart rate measured with SphygmoCor-XCEL

    Change from baseline at 6 weeks and 12 weeks in heart rate (pbm)

    Time frame: Baseline, 6 weeks and 12 weeks

  15. Change in Lean Mass measured by Dual-Energy X-ray Absorptiometry (DXA)

    Change from baseline in Lean Mass measured by Dual-Energy X-ray Absorptiometry (DXA)

    Time frame: Baseline and 12 weeks

  16. Change in Body Composition Measured by Bioimpedance (InBody 770)

    Change in Body Composition (fat mass and fat-free mass, Kg) measured by Bioimpedance (InBody 770)

    Time frame: Baseline and 12 weeks

  17. Change in Quality of life assessed by The 36-Item Short Form Health Survey questionnaire (SF-36)

    Change from baseline to 12 weeks in tThe 36-Item Short Form Health Survey questionnaire (SF-36) \[Score ranging from 0 to 100\]

    Time frame: baseline, 12 weeks

  18. Change in Quality of Life Measured by EuroQol 5-Dimensions (EQ-5D)

    Change from baseline to Week 12 in health-related quality of life as measured by the EuroQol 5-Dimensions (EQ-5D) questionnaire. The EQ-5D assesses five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted to a single EQ-5D index value using a country-specific value set. The EQ-5D index score typically ranges from less than 0 (health states worse than death) to 1.0 (full health).

    Time frame: Baseline, 12 weeks

  19. Change in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI)

    Change from baseline to Week 12 in sleep quality assessed using the validated Pittsburgh Sleep Quality Index (PSQI) questionnaire. Scores range from 0 to 21, with higher scores indicating worse sleep quality.

    Time frame: Baseline and 12 weeks

  20. Change in Sleep Quality Measured by SATED Sleep Questionnaire

    Change from baseline to Week 12 in sleep quality assessed using the SATED questionnaire. Scores range from 0 to 24, with higher scores indicating better sleep quality.

    Time frame: Baseline, 12 weeks

  21. Change in Sleep Efficiency Measured by Wearable Device

    Change from baseline to Week 12 in sleep efficiency assessed using a wearable device (e.g., OURA ring). Sleep efficiency is reported as a percentage (%), with higher values indicating better sleep quality.

    Time frame: Baseline and Week 12

Other outcomes

  1. Study participation and retention rates

    Participation rate defined as the percentage of eligible participants enrolled, and dropout rate defined as the percentage of participants who discontinue the study and reasons for dropout

    Time frame: 12 weeks

  2. Adherence to supplement intervention

    Supplement adherence, measured as the proportion (%) and total number of prescribed doses taken, as verified by returned empty sachet counts at each visit.

    Time frame: 12 weeks

  3. Adherence to exercise intervention

    Adherence to the exercise intervention, assessed as the number and percentage of scheduled exercise sessions attended, as recorded by study staff.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • MD11 Clinical Research Centre, #03-01, 10 Medical Drive
    Singapore, 117597, Singapore
    Recruiting
    • Mazzarine Dotou, PhD, MBA · Contactmazzarine@nus.edu.sg · +65 87264704
    • Andrea Britta Maier, MD, PhD, FRACP · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the primary, secondary and other outcome measures reported in this study, will be made available on request. Data will be fully de-identified and will not include direct identifiers. Raw data (e.g., DNA methylation, microbiome sequencing) may be shared in processed or aggregated form, as appropriate, to minimize re-identification risk.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: IPD and supporting information will become available after study completion and publication of the main findings, with the end date to be determined.

Access criteria: Access to de-identified IPD will be provided upon reasonable request to qualified researchers with a methodologically sound proposal and appropriate ethical approval. Requests will be reviewed by the study investigators and data will be shared under a data use agreement specifying permitted uses, data security requirements, and restrictions on re-identification..

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Apr 2026, 7 months after the start.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 7 months is below that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 6, 2026
StartActual
Sep 22, 2025
Primary completionEst.
Apr 30, 2026
CompletionEst.
May 8, 2026
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07454616
Responsible party
Andrea Maier (Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research, National University of Singapore) — Principal investigator
First posted
Mar 6, 2026
Start date
Sep 22, 2025
Primary completion
Apr 30, 2026 (estimated)
Completion
May 8, 2026 (estimated)
Last update
Mar 6, 2026

Study contacts

Mazzarine Dotou, PhD
Contact
mazzarine@nus.edu.sg
+65 87264704
Prof. Andrea Britta Maier, MD, PHD, FRACP
principal investigator · National University of Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion